303 related articles for article (PubMed ID: 18520302)
1. Heat shock protein 90 inhibition in lung cancer.
Shimamura T; Shapiro GI
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S152-9. PubMed ID: 18520302
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Shimamura T; Lowell AM; Engelman JA; Shapiro GI
Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
5. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
[TBL] [Abstract][Full Text] [Related]
6. The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism.
Kanugovi Vijayavittal A; Amere Subbarao S
Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118943. PubMed ID: 33359710
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 inhibitors in non-small-cell lung cancer.
Pillai RN; Ramalingam SS
Curr Opin Oncol; 2014 Mar; 26(2):159-64. PubMed ID: 24463348
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC
J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
[TBL] [Abstract][Full Text] [Related]
12. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
13. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
Khaledian B; Taguchi A; Shin-Ya K; Kondo-Ida L; Kagaya N; Suzuki M; Kajino T; Yamaguchi T; Shimada Y; Takahashi T
Cancer Sci; 2021 Mar; 112(3):1225-1234. PubMed ID: 33370472
[TBL] [Abstract][Full Text] [Related]
15. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.
O'Connell BC; O'Callaghan K; Tillotson B; Douglas M; Hafeez N; West KA; Stern H; Ali JA; Changelian P; Fritz CC; Palombella VJ; McGovern K; Kutok JL
PLoS One; 2014; 9(12):e115228. PubMed ID: 25542032
[TBL] [Abstract][Full Text] [Related]
16. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.
Ahsan A; Ramanand SG; Whitehead C; Hiniker SM; Rehemtulla A; Pratt WB; Jolly S; Gouveia C; Truong K; Van Waes C; Ray D; Lawrence TS; Nyati MK
Neoplasia; 2012 Aug; 14(8):670-7. PubMed ID: 22952420
[TBL] [Abstract][Full Text] [Related]
17. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Xu W; Soga S; Beebe K; Lee MJ; Kim YS; Trepel J; Neckers L
Br J Cancer; 2007 Sep; 97(6):741-4. PubMed ID: 17712310
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
20. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Edwards A; Li J; Atadja P; Bhalla K; Haura EB
Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]